Authors
Chuanyan Lin, Liyong Yuan, Jun Shi, Lingsi Kong, Ni Luo, Jianlin Wang
Published in
Therapeutics and clinical risk management. Volume 21. Pages 747-755. Epub May 23, 2025.
Abstract
Esketamine and dexmedetomidine are commonly used sedatives in surgery, which can result in minimal respiratory depression and analgesic activity. This study investigated the sedative effect of esketamine combined with dexmedetomidine on patients undergoing spinal tumor (ST) surgery.
We did a retrospective analysis at the Anesthesiology Department of Ningbo City's the sixth Hospital. They studied 75 ST surgery patients who got esketamine in combination with dexmedetomidine (Group ED) between April 2022 and June 2024. In a 1:1 cohort, compare these individuals to those who only received dexmedetomidine at the same time period (Group D). The primary outcome is perioperative hemodynamic status. The secondary outcomes were pain intensity, intraoperative neurophysiological monitoring (IONM), and the occurrence of adverse responses.
Compared with group E, the group ED had lower mean arterial pressure (MAP), heart rate (HR), and visual-analogue scale (VAS) scores after the start of surgery (all P<0.05). There was no significant difference in the waiting time for perioperative motor evoked potential (MEP) and the intensity of the first induced MEP current between the two groups (all P>0.05); The Group ED first induced MEP amplitude, somatosensory evoked potential (SEP) amplitude, and MEP amplitude greater than the Group D, while SEP latency and MEP latency were smaller than the Group D (all P<0.05). There was no significant difference in the incidence of perioperative adverse events between the two groups (P>0.05).
Compared with dexmedetomidine alone, the combination of esketamine and dexmedetomidine during ST surgery can demonstrated superior sedation and pain control without increasing adverse event risk, making it a viable alternative for ST surgery anesthesia.
PMID:
40433631
Bibliographic data and abstract were imported from PubMed on 28 May 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0